January 20, 2012 - BridgePoint Medical Inc. this week signed an agreement with Covidien to exclusively license the rights to its peripheral vascular products used to treat chronic total occlusions (CTO).  The agreement includes the BigBoss and Mantaray catheters and the Mantaray guidewire. The terms of the agreement were not disclosed.

January 20, 2012 – Nuclear cardiology imaging company Positron Corp. this week acquired Manhattan Isotope Technology LLC (MIT). Positron has acquired all of the assets, business operations and retained all employees of MIT. In exchange, MIT shall receive cash advances, assumption of certain indebtedness and earn-out consideration of $3.5 million based on 20 percent of the net income from sales relating to radioisotope and radiopharmaceutical operations of MIT.

January 20, 2012 - Robert J. Kennedy, M.D., interventional radiologist at Holmes Regional Medical Center in Melbourne, Fla., this week presented data on thrombus resolution and hemodynamic recovery using ultrasound accelerated thrombolysis in acute pulmonary embolism (PE) at the International Symposium on Endovascular Therapy (ISET).

January 19, 2011 –– Interim analysis of the FAME II trial found a highly statistically significant reduction in the need for hospital readmission and urgent revascularization when fractional flow reserve (FFR)-guided assessment was used to direct treatment in patients with coronary artery disease. As a result of the positive interim analysis, the FAME II independent data safety monitoring board (DSMB) has recommended investigators stop patient enrollment in this trial, as the DSMB considers it unethical to continue to randomize patients to optimal medical therapy (OMT) alone.

 

January 19, 2012 – New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor can achieve very fast blood thinning effects when needed to protect from heart attacks, but also dissipates rapidly so patients can undergo surgery without the excessive bleeding often associated with blood thinning medications.

 

January 18, 2011 – Medtronic Inc. announced the CE mark and international launch of the Endurant II AAA stent graft system, which can treat patients with abdominal aortic aneurysms through endovascular aortic repair (EVAR).

January 18, 2011  – Epicardial ablation device vendor nContact Inc. said data presented by physicians in two posters at the 17th Annual International Boston Atrial Fibrillation Symposium may change how physicians think about treating atrial fibrillation (AF) patients with enlarged atria.

January 18, 2012 — Baptist Cardiac & Vascular Institute of Miami announced a partnership with the University of Heidelberg, one of the largest and most important centers for patient care, medical research and teaching in Europe, for hands-on access to the latest medical innovations.

January 18, 2012 — Boston Scientific reported nine-month clinical endpoint data from its ORION trial, demonstrating positive outcomes for the Epic self-expanding nitinol stent in patients with iliac artery disease.

January 18, 2012 — PLC Systems Inc. announced that final results from the MYTHOS investigator-sponsored clinical trial of RenalGuard in Italy have been published in the January 2012 issue of Journal of the American College of Cardiology – Cardiovascular Interventions, a peer-reviewed journal of the American College of Cardiology. The results from this trial showed RenalGuard as better than the current standard-of-care at reducing rates of contrast-induced nephropathy (CIN) and in-hospital dialysis in at-risk patients undergoing certain imaging procedures.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now